Using regionally delivered autologous mesothelin-targeted CAR T cells in the treatment of malignant pleural disease

Importance of capacity development for African researchers

KEYNOTE 189: Targeting NSCLC patients with brain and liver metastases

MYSTIC: Developing biomarkers for metastatic NSCLC

TATTON: Updated results for patients with EGFR-mutant NSCLC

Mesothelin-targeted CAR T-cell therapy safe, shows early promise in patients with advanced solid tumours

Immune checkpoint inhibitor combination efficacious for patients with high-grade neuroendocrine carcinoma

HER2-targeted CAR T-cell therapy safe and showing promising antitumour activity in patients with advanced sarcoma

Cancer preventive vaccine showed promising results in preclinical model of Lynch syndrome

Umbralisib shows early promise for patients with marginal zone lymphoma

KEYNOTE trials show pembrolizumab benefited patients with advanced small cell lung cancer

Gilteritinib improved survival for patients with acute myeloid leukaemia